Jazz Pharma (JAZZ): B. Riley FBR Keeps “Buy” Rating Today, Has a Target of $190.0/Share

November 8, 2018 - By Kristen Paramore

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment increased to 1.52 in 2018 Q2. Its up 0.50, from 1.02 in 2018Q1. It is positive, as 25 investors sold Jazz Pharmaceuticals plc shares while 88 reduced holdings. 79 funds opened positions while 93 raised stakes. 54.43 million shares or 4.78% more from 51.95 million shares in 2018Q1 were reported.

Hillsdale Management stated it has 300 shares. Moreover, Lsv Asset has 0.08% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Barclays Public Limited Company has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Ubs Asset Mgmt Americas Inc invested in 0% or 266,865 shares. Ranger Inv Lp invested in 0.02% or 1,424 shares. Confluence Invest invested in 0.02% or 5,453 shares. Commonwealth State Bank Of has 591 shares. Sit Invest Assoc Inc owns 5,700 shares. Maverick Ltd holds 41,910 shares. Tekla Limited Company holds 110,452 shares or 0.72% of its portfolio. Tiverton Asset Mngmt Limited Liability owns 1,148 shares or 0.01% of their US portfolio. Two Sigma Securities Limited Liability Company owns 1,354 shares. Banced invested in 3,202 shares. Us Savings Bank De invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Alpine Woods Cap Ltd, a New York-based fund reported 23,120 shares.

Since May 11, 2018, it had 0 buys, and 17 sales for $5.27 million activity. Young Matthew P. sold $113,890 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, September 17. McSharry Heather Ann had sold 715 shares worth $126,276 on Thursday, August 9. 715 shares were sold by Gray Peter, worth $126,277 on Thursday, August 9. ENRIGHT PATRICK G also sold $1.71M worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares. Shares for $116,563 were sold by O’Keefe Kenneth W. On Friday, June 1 the insider COZADD BRUCE C sold $1.18 million.

Jazz Pharma (JAZZ) Rating Reaffirmed

B. Riley FBR now has a $190.0 target price on the $8.59 billion market cap company or 34.25 % upside potential. In analysts report sent to investors and clients on Thursday morning, Jazz Pharma (JAZZ) shares have had their “Buy” Rating maintained by equity research analysts at B. Riley FBR.

The stock increased 1.27% or $1.78 during the last trading session, reaching $142.19. About 1.74M shares traded or 250.83% up from the average. Jazz Pharmaceuticals plc (JAZZ) has risen 6.65% since November 9, 2017 and is uptrending. It has underperformed by 8.97% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.59 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 20.06 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Benzinga.com which released: “88 Biggest Movers From Yesterday” on November 08, 2018, also Nasdaq.com with their article: “Why Jazz Pharmaceuticals plc Stock Is Slumping Today” published on November 07, 2018, Seekingalpha.com published: “Jazz Pharmaceuticals beats by $0.26, misses on revenue” on November 06, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Streetinsider.com and their article: “Jazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital” published on November 07, 2018 as well as Seekingalpha.com‘s news article titled: “Jazz settles Xyrem patent dispute with Amneal Pharma; shares up 2% after hours” with publication date: October 11, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.